市場調査レポート

商品コード

1671195

遺伝子治療の世界市場：市場規模・シェア・動向、業界分析 (治療領域別・ベクターの種類別・アプローチ別・投与経路別・地域別)、将来予測 (2025年～2034年)

Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area, Vector Type, Approach, Route of Administration, and Region - Market Forecast 2025-2034

出版日: 2025年02月01日
発行: Polaris Market Research
ページ情報: 英文 154 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,250 610,172円

レポートPDFを1名のみがご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 5,250 753,742円

レポートPDFを20名様までご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 6,250 897,312円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Polaris Market Research社の最新調査によると、遺伝子治療の市場規模は2034年までに272億5,020万米ドルに達すると予測されています。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

遺伝子治療は、患者の細胞内の不健康な遺伝子を修正または置換し、病気を治療または予防するものです。遺伝子工学の急速な進歩は、分子生物学への理解の深まりとともに、遺伝子治療を実験段階から実際の臨床応用へと押し上げました。研究者やバイオ製薬会社は安全で効果的な治療法の開発に多額の投資を行っており、一方で規制機関は遺伝子治療市場の拡大を加速させるために承認プロセスを合理化しています。

遺伝子治療の需要は、デュシェンヌ型筋ジストロフィー（DMD）、鎌状赤血球症、血友病、嚢胞性線維症などの遺伝性疾患の有病率の増加により急増しています。症状管理を中心とした従来の治療法とは異なり、遺伝子治療はこれらの疾患の根本的な原因を遺伝子レベルで標的とします。この標的を絞ったアプローチは治療効果を高め、長期的あるいは永続的な緩和の可能性を提供します。近年、CRISPR-Cas9やジンクフィンガーヌクレアーゼ（ZFN）といった遺伝子編集技術の飛躍的な進歩により、より正確で効率的な遺伝子改変が可能になりました。

遺伝子ベースの治療に対する規制当局の承認件数の増加が、遺伝子治療市場の成長を後押ししています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの政府機関は、こうした治療法の変革の可能性を認識しています。これらの機関は有望な候補の承認プロセスを促進しています。脊髄性筋萎縮症（SMA）に対するゾルゲンスマや遺伝性網膜疾患に対するLuxturnaのような治療が目覚ましい臨床的成功を収めたことで、遺伝子ベースの治療や処置がより広く採用される道が開かれました。

遺伝子治療市場：分析概要

治療分野別では、身体的・心理的に大きな影響を及ぼす疾患やその治療が蔓延していることから、2024年の遺伝子治療市場シェアをリードするのはがん疾患分野です。

ベクターの種類別では、ウイルスセグメントが、さまざまながん、単発性疾患、感染症に対して標的細胞に遺伝子を効果的かつ効率的に送達することから、遺伝子治療市場の売上シェアをリードしています。

北米が遺伝子治療市場をリードしているのは、強固な研究インフラ、高度な医療システム、臨床試験への多額の資金提供、新規遺伝子治療の迅速な開発と承認を可能にするFDAを中心とした支持的な規制の枠組みによるものです。

世界の主要企業としては、アベオナ・セラピューティック、ノバルティスAG、スパーク・セラピューティクスLLC、ギリアド・サイエンシズ、ブリストル・マイヤーズ・スクイブ、アドバウム・バイオテクノロジーズ、アルナイラム・ファーマシューティカルズ、アメリカン・ジーン・テクノロジーズ、アプライド・ジェネティック・テクノロジーズ・コーポレーション、バイオジェン、ウルトラジェニックスなどが挙げられます。

遺伝子治療：業界概要
遺伝子治療の市場力学
- 促進要因と機会
  - 遺伝子治療開発への承認と投資の増加
  - 対象疾患の蔓延拡大
  - 高齢化人口の増加
- 抑制要因と課題
  - 製造と物流の課題
  - 処置費用の高さと曖昧な規制枠組みの存在
  - 医療インフラの不足
ポーターのファイブフォース分析
- サプライヤーの交渉力 (高)
- 新規参入企業の脅威 (低)
- バイヤーの交渉力 (中)
- 代替製品の脅威 (低)
- 企業間競争 (高)
PESTLE分析
COVID-19の影響分析と業界動向

第5章遺伝子治療市場：治療領域別の評価

イントロダクション
自己免疫疾患
心血管疾患
皮膚疾患
血液疾患
代謝障害
筋肉関連疾患
腫瘍性疾患
その他の治療領域

第6章遺伝子治療市場：ベクターの種類別の評価

イントロダクション
ウイルス
- レトロウイルスベクター
  - ガンマレトロウイルスベクター
  - レンチウイルスベクター
- アデノ随伴ウイルスベクター
- その他のウイルスベクター
非ウイルス性
- オリゴヌクレオチド
- その他の非ウイルスベクター

第7章遺伝子治療市場：アプローチ別の評価

イントロダクション
遺伝子増強
腫瘍溶解性ウイルス療法
免疫療法
その他のアプローチ

第8章遺伝子治療市場：投与経路別の評価

イントロダクション
関節内
小脳内
皮内
筋肉内
腫瘍内
静脈内
膀胱内
硝子体内
網膜下
その他

第9章遺伝子治療市場：地域別の評価

イントロダクション
北米
- 米国
- カナダ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- オランダ
- オーストリア
アジア太平洋
- 中国
- インド
- 日本
- 韓国
ラテンアメリカ
- ブラジル
- メキシコ
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦

第10章競合情勢

主な市場参入企業：分類
戦略的枠組み
ベンダー情勢
戦略の分類
- 事業提携/事業協力/契約
- 拡張/合併/買収
- 製品開発/新発売

第11章企業プロファイル

Sangamo Biosciences
Voyager Therapeutics
Ultragenyx
GlaxoSmithKline
Gilead Sciences Inc
Bristol Myers Squibb
Novartis AG
Spark Therapeutics LLC
Bluebird Bio

図表

List of Tables

Table 1 Global Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 1 Global Gene Therapy Market, by Autoimmune Disorders, 2020-2034 (USD Million)
Table 2 Global Gene Therapy Market, by Cardiovascular Diseases, 2020-2034 (USD Million)
Table 3 Global Gene Therapy Market, by Dermatological Disorders, 2020-2034 (USD Million)
Table 4 Global Gene Therapy Market, by Hematological Disorders, 2020-2034 (USD Million)
Table 5 Global Gene Therapy Market, by Metabolic Disorders, 2020-2034 (USD Million)
Table 6 Global Gene Therapy Market, by Muscle-related Diseases, 2020-2034 (USD Million)
Table 7 Global Gene Therapy Market, by Oncological Disorders, 2020-2034 (USD Million)
Table 8 Global Gene Therapy Market, by Other Therapeutic Areas, 2020-2034 (USD Million)
Table 9 Global Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 10 Global Gene Therapy Market, by Viral, 2020-2034 (USD Million)
Table 11 Global Gene Therapy Market, by Retroviral vectors, 2020-2034 (USD Million)
Table 12 Global Gene Therapy Market, by Gamma-retroviral vectors, 2020-2034 (USD Million)
Table 13 Global Gene Therapy Market, by Lentiviral vectors, 2020-2034 (USD Million)
Table 14 Global Gene Therapy Market, by Adeno-associated virus vectors, 2020-2034 (USD Million)
Table 15 Global Gene Therapy Market, by Other viral vectors, 2020-2034 (USD Million)
Table 16 Global Gene Therapy Market, by Non-Viral, 2020-2034 (USD Million)
Table 17 Global Gene Therapy Market, by Oligonucleotides, 2020-2034 (USD Million)
Table 18 Global Gene Therapy Market, by Other non-viral vectors, 2020-2034 (USD Million)
Table 19 Global Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 20 Global Gene Therapy Market, by Gene Augmentation, 2020-2034 (USD Million)
Table 21 Global Gene Therapy Market, by Oncolytic Viral Therapy, 2020-2034 (USD Million)
Table 22 Global Gene Therapy Market, by Immunotherapy, 2020-2034 (USD Million)
Table 23 Global Gene Therapy Market, by Other Approaches, 2020-2034 (USD Million)
Table 24 Global Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 25 Global Gene Therapy Market, by Intraarticular, 2020-2034 (USD Million)
Table 26 Global Gene Therapy Market, by Intracerebellar, 2020-2034 (USD Million)
Table 27 Global Gene Therapy Market, by Intradermal, 2020-2034 (USD Million)
Table 28 Global Gene Therapy Market, by Intramuscular, 2020-2034 (USD Million)
Table 29 Global Gene Therapy Market, by Intratumoral, 2020-2034 (USD Million)
Table 30 Global Gene Therapy Market, by Intravenous, 2020-2034 (USD Million)
Table 31 Global Gene Therapy Market, by Intravesical, 2020-2034 (USD Million)
Table 32 Global Gene Therapy Market, by Intravitreal, 2020-2034 (USD Million)
Table 33 Global Gene Therapy Market, by Subretinal, 2020-2034 (USD Million)
Table 34 Global Gene Therapy Market, by Others, 2020-2034 (USD Million)
Table 35 Gene Therapy Market Assessment, By Geography, 2020-2034 (USD Million)
Table 36 North America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 37 North America Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 38 North America Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 39 North America Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
Table 40 North America Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 41 North America Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 42 North America Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 43 U.S. Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 44 U.S. Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 45 U.S. Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 46 U.S. Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 47 U.S. Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 48 U.S. Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 49 U.S. Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 50 Canada Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 51 Canada Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 52 Canada Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 53 Canada Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 54 Canada Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 55 Canada Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 56 Canada Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 57 Europe Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 58 Europe Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 59 Europe Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 60 Europe Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 61 Europe Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 62 Europe Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 63 Europe Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 64 Germany Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 65 Germany Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 66 Germany Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 67 Germany Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
Table 68 Germany Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 69 Germany Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 70 Germany Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 71 UK Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 72 UK Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 73 UK Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 74 UK Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 75 UK Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 76 UK Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 77 UK Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 78 France Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 79 France Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 80 France Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 81 France Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 82 France Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 83 France Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 84 France Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 85 Italy Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 86 Italy Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 87 Italy Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 88 Italy Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 89 Italy Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 90 Italy Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 91 Italy Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 92 Spain Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 93 Spain Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 94 Spain Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 95 Spain Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
Table 96 Spain Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 97 Spain Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 98 Spain Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 99 Netherlands Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 100 Netherlands Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 101 Netherlands Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 102 Netherlands Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 103 Netherlands Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 104 Netherlands Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 105 Netherlands Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 106 Austria Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 107 Austria Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 108 Austria Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 109 Austria Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 110 Austria Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 111 Austria Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 112 Austria Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 113 Asia Pacific Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 114 Asia Pacific Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 115 Asia Pacific Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 116 Asia Pacific Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 117 Asia Pacific Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 118 Asia Pacific Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 119 Asia Pacific Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 120 China Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 121 China Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 122 China Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 123 China Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
Table 124 China Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 125 China Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 126 China Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 127 India Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 128 India Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 129 India Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 130 India Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 131 India Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 132 India Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 133 India Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 134 Japan Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 135 Japan Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 136 Japan Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 137 Japan Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 138 Japan Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 139 Japan Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 140 Japan Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 141 South Korea Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 142 South Korea Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 143 South Korea Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 144 South Korea Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 145 South Korea Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 146 South Korea Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 147 South Korea Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 148 Latin America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 149 Latin America Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 150 Latin America Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 151 Latin America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 152 Latin America Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 153 Latin America Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 154 Latin America Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 155 Brazil Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 156 Brazil Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 157 Brazil Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 158 Brazil Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 159 Brazil Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 160 Brazil Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 161 Brazil Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 162 Mexico Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 163 Mexico Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 164 Mexico Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 165 Mexico Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
Table 166 Mexico Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 167 Mexico Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 168 Mexico Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 169 Middle East & Africa Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 170 Middle East & Africa Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 171 Middle East & Africa Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 172 Middle East & Africa Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 173 Middle East & Africa Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 174 Middle East & Africa Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 175 Middle East & Africa Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 176 Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 177 Saudi Arabia Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 178 Saudi Arabia Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 179 Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 180 Saudi Arabia Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 181 Saudi Arabia Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 182 Saudi Arabia Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
Table 183 UAE Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
Table 184 UAE Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
Table 185 UAE Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
Table 186 UAE Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
Table 187 UAE Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
Table 188 UAE Gene Therapy Market, By Approach, 2020-2034 (USD Million)
Table 189 UAE Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)

List of Figures

Figure 1. Executive Summary
Figure 2. Research Methodology: Top Down & Bottom-Up Approach
Figure 3. Market by Geography, 2020-2034 (USD Million)
Figure 6. Porter's Five Forces
Figure 7. PEST Analysis
Figure 8. Market by Therapeutic Area
Figure 9. Global Gene Therapy Market, By Therapeutic Area, 2024 & 2034 (USD Million)
Figure 10. Market by Vector Type
Figure 11. Global Gene Therapy Market, By Vector Type, 2024 & 2034 (USD Million)
Figure 12. Market by Approach
Figure 13. Global Gene Therapy Market, By Approach, 2024 & 2034 (USD Million)
Figure 14. Market by Route of Administration
Figure 15. Global Gene Therapy Market, By Route of Administration, 2024 & 2034 (USD Million)
Figure 16. Gene Therapy Market Assessment, By Geography, 2024 & 2034 (USD Million)

Product Code: PM1084

The gene therapy market size is expected to reach USD 27,250.20 million by 2034, according to a new study by Polaris Market Research. The report "Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area (Autoimmune Disorders, Cardiovascular Diseases, Dermatological Disorders, Hematological Disorders, Metabolic Disorders, Muscle-Related Diseases, Oncological Disorders, and Others), Vector Type, Approach, Route of Administration, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gene therapy involves modifying or replacing unhealthy genes within a patient's cells to treat or prevent disease. Rapid advancements in genetic engineering, along with an increasing understanding of molecular biology, have propelled gene therapy from experimental stages to real-world clinical applications. Researchers and biopharmaceutical companies are investing heavily in developing safe and effective therapies, while regulatory bodies are streamlining approval processes to accelerate gene therapy market expansion.

The demand for gene therapy has surged due to the increasing prevalence of genetic disorders such as Duchenne muscular dystrophy (DMD), sickle cell disease, hemophilia, and cystic fibrosis. Unlike traditional treatment methods that primarily focus on symptom management, gene therapy targets the underlying cause of these diseases at the genetic level. This targeted approach enhances treatment efficacy and offers the potential for long-term or even permanent relief. In recent years, significant breakthroughs in gene-editing technologies, such as CRISPR-Cas9 and zinc finger nucleases (ZFNs), have enabled more precise and efficient gene modifications.

The rising number of regulatory approvals for gene-based treatments is propelling the gene therapy market growth. Government agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recognized the transformative potential of these therapies. They are expediting the approval process for promising candidates. Therapies such as Zolgensma for spinal muscular atrophy (SMA) and Luxturna for inherited retinal disease have demonstrated remarkable clinical success, paving the way for broader adoption of gene-based therapies or treatments.

Gene Therapy Market Report Highlights

Based on therapeutic area, the oncological disorders segment leads the gene therapy market share in 2024 due to the prevalence of significant physical and psychological impacts of the disease and its treatment.

By vector type, the viral segment leads gene therapy market revenue share due to its effective and efficient delivering genes to the targeted cells for various cancers, monogenic and infectious diseases.

North America leads the gene therapy market due to its robust research infrastructure, advanced healthcare system, significant funding for clinical trials, and a supportive regulatory framework, particularly from the FDA, which allows for rapid development and approval of new gene therapies.

A few global key market players are Abeona Therapeutic, Novartis AG, Spark Therapeutics LLC, Gilead Sciences Inc., Bristol Myers Squibb, Adverum Biotechnologies, Alnylam Pharmaceuticals, American Gene Technologies, Applied Genetic Technologies Corporation, Biogen, and Ultragenyx.

Polaris Market Research has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region:

By Type Therapeutic Area Outlook (Revenue, USD Million, 2020-2034)

Autoimmune Disorders
Cardiovascular Diseases
Dermatological Disorders
Hematological Disorders
Metabolic Disorders
Muscle-Related Diseases
Oncological Disorders
Others

By Vector Type Outlook (Revenue, USD Million, 2020-2034)

Viral
Non-Viral

By Approach Outlook (Revenue, USD Million, 2020-2034)

Gene Augmentation
Oncolytic Viral Therapy
Immunotherapy
Other Approaches

By Route of Administration Outlook (Revenue, USD Million, 2020-2034)

Intraarticular
Intracerebellar
Intradermal
Intramuscular
Intratumoral
Intravenous
Intravesical
Intravitreal
Subretinal
Others

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Chapter 1. Introduction

1.1 Report Description
- 1.1.1 Objectives of the Study
- 1.1.2 Market Scope
- 1.1.3 Assumptions
1.2 Stakeholders

Chapter 2. Executive Summary

Chapter 3. Research Methodology

3.1 Overview
- 3.1.1 Data Mining
3.2 Data Sources
- 3.2.1 Primary Sources
- 3.2.2 Secondary Sources

Chapter 4. Gene Therapy Market Insights

4.1 Gene Therapy - Industry snapshot
4.1 Gene Therapy Market Dynamics
- 4.1.1 Drivers and Opportunities
  - 4.1.1.1 Rising Approval and Investments in Gene Therapy Development
  - 4.1.1.2 Growing Prevalence of Target Diseases
  - 4.1.1.3 Growing Geriatric Population Base
- 4.1.2 Restraints and Challenges
  - 4.1.2.1 Manufacturing and logistics challenges
  - 4.1.2.2 High Procedure Costs and Presence of Ambiguous Regulatory Framework
  - 4.1.2.3 Lack of Healthcare Infrastructure
4.2 Gene Therapy Market - Porter's Five Forces
- 4.2.1 Bargaining Power of Suppliers (High)
- 4.2.2 Threats of New Entrants: (Low)
- 4.2.3 Bargaining Power of Buyers (Moderate)
- 4.2.4 Threat of Substitute (Low)
- 4.2.5 Rivalry among existing firms (High)
4.3 Gene Therapy Market - PEST Analysis
4.4 Covid-19 Impact Analysis & Industry Trends

Chapter 5. Gene Therapy Market Assessment by Therapeutic Area

5.1 Introduction
5.2 Autoimmune Disorders
5.3 Cardiovascular Diseases
5.4 Dermatological Disorders
5.5 Hematological Disorders
5.6 Metabolic Disorders
5.7 Muscle-related Diseases
5.8 Oncological Disorders
5.9 Other Therapeutic Areas

Chapter 6. Gene Therapy Market Assessment by Vector Type

6.1 Introduction
6.2 Viral
- 6.2.1 Retroviral vectors
  - 6.2.1.1 Gamma-retroviral vectors
  - 6.2.1.2 Lentiviral vectors
- 6.2.2 Adeno-associated virus vectors
- 6.2.3 Other viral vectors
6.3 Non-Viral
- 6.3.1 Oligonucleotides
- 6.3.2 Other non-viral vectors

Chapter 7. Gene Therapy Market Assessment by Approach

7.1 Introduction
7.2 Gene Augmentation
7.1 Oncolytic Viral Therapy
7.2 Immunotherapy
7.3 Other Approaches

Chapter 8. Gene Therapy Market Assessment by Route of Administration

8.1 Introduction
8.2 Intraarticular
8.3 Intracerebellar
8.4 Intradermal
8.5 Intramuscular
8.6 Intratumoral
8.7 Intravenous
8.8 Intravesical
8.9 Intravitreal
8.10 Subretinal
8.11 Others

Chapter 9. Gene Therapy Market Assessment by Region

9.1 Introduction
9.2 Gene Therapy Market - North America
- 9.2.1 Gene Therapy Market - U.S.
- 9.2.2 Gene Therapy Market - Canada
9.3 Gene Therapy Market - Europe
- 9.3.1 Gene Therapy Market - Germany
- 9.3.2 Gene Therapy Market - UK
- 9.3.3 Gene Therapy Market - France
- 9.3.4 Gene Therapy Market - Italy
- 9.3.5 Gene Therapy Market - Spain
- 9.3.6 Gene Therapy Market - Netherlands
- 9.3.7 Gene Therapy Market - Austria
9.4 Gene Therapy Market - Asia Pacific
- 9.4.1 Gene Therapy Market - China
- 9.4.2 Gene Therapy Market - India
- 9.4.3 Gene Therapy Market - Japan
- 9.4.4 Gene Therapy Market - South Korea
9.5 Gene Therapy Market - Latin America
- 9.5.1 Gene Therapy Market - Brazil
- 9.5.2 Gene Therapy Market - Mexico
9.6 Gene Therapy Market - Middle East & Africa
- 9.6.1 Gene Therapy Market - Saudi Arabia
- 9.6.2 Gene Therapy Market - UAE

Chapter 10. Competitive Landscape

10.1 Key Market Players: Categorization
10.2 Strategy Framework
10.3 Vendor Landscape
10.4 Strategies Categorization
- 10.4.1 Partnerships/Collaborations/Agreements
- 10.4.2 Expansions/Mergers/Acquisitions
- 10.4.3 Product Development/New Launch

Chapter 11. Company Profiles

11.1 Sangamo Biosciences
- 11.1.1 Business Overview
- 11.1.2 Financial Snapshot
- 11.1.3 Products and Services
- 11.1.4 Recent Developments
11.2 Voyager Therapeutics
- 11.2.1 Business Overview
- 11.2.2 Financial Snapshot
- 11.2.3 Products and Services
- 11.2.4 Recent Developments
11.3 Ultragenyx
- 11.3.1 Business Overview
- 11.3.2 Financial Snapshot
- 11.3.3 Products and Services
- 11.3.4 Recent Developments
11.4 GlaxoSmithKline
- 11.4.1 Business Overview
- 11.4.2 Financial Snapshot
- 11.4.3 Products and Services
- 11.4.4 Recent Developments
11.5 Gilead Sciences Inc
- 11.5.1 Business Overview
- 11.5.2 Financial Snapshot
- 11.5.3 Products and Services
- 11.5.4 Recent Developments
11.6 Bristol Myers Squibb
- 11.6.1 Business Overview
- 11.6.2 Financial Snapshot
- 11.6.3 Products and Services
- 11.6.4 Recent Developments
11.7 Novartis AG
- 11.7.1 Business Overview
- 11.7.2 Financial Snapshot
- 11.7.3 Products and Services
- 11.7.4 Recent Developments
11.8 Spark Therapeutics LLC
- 11.8.1 Business Overview
- 11.8.2 Products and Services
- 11.8.3 Recent Developments
11.9 Bluebird Bio
- 11.9.1 Business Overview
- 11.9.2 Recent Developments
- 11.9.3 Products and Services
- 11.9.4 Recent Developments

遺伝子治療の世界市場：市場規模・シェア・動向、業界分析 (治療領域別・ベクターの種類別・アプローチ別・投与経路別・地域別)、将来予測 (2025年～2034年)

Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area, Vector Type, Approach, Route of Administration, and Region - Market Forecast 2025-2034

遺伝子治療市場：分析概要

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章分析手法

第4章遺伝子治療市場の洞察

第5章遺伝子治療市場：治療領域別の評価

第6章遺伝子治療市場：ベクターの種類別の評価

第7章遺伝子治療市場：アプローチ別の評価

第8章遺伝子治療市場：投与経路別の評価

第9章遺伝子治療市場：地域別の評価

第10章競合情勢

第11章企業プロファイル

List of Tables

List of Figures

Gene Therapy Market Report Highlights

By Type Therapeutic Area Outlook (Revenue, USD Million, 2020-2034)

By Vector Type Outlook (Revenue, USD Million, 2020-2034)

By Approach Outlook (Revenue, USD Million, 2020-2034)

By Route of Administration Outlook (Revenue, USD Million, 2020-2034)

By Regional Outlook (Revenue, USD Million, 2020-2034)

Table of Contents

Chapter 1. Introduction

Chapter 2. Executive Summary

Chapter 3. Research Methodology

Chapter 4. Gene Therapy Market Insights

Chapter 5. Gene Therapy Market Assessment by Therapeutic Area

Chapter 6. Gene Therapy Market Assessment by Vector Type

Chapter 7. Gene Therapy Market Assessment by Approach

Chapter 8. Gene Therapy Market Assessment by Route of Administration

Chapter 9. Gene Therapy Market Assessment by Region

Chapter 10. Competitive Landscape

Chapter 11. Company Profiles

遺伝子治療の世界市場：市場規模・シェア・動向、業界分析 (治療領域別・ベクターの種類別・アプローチ別・投与経路別・地域別)、将来予測 (2025年～2034年)

Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area, Vector Type, Approach, Route of Administration, and Region - Market Forecast 2025-2034

遺伝子治療市場：分析概要

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 分析手法

第4章 遺伝子治療市場の洞察

第5章 遺伝子治療市場：治療領域別の評価

第6章 遺伝子治療市場：ベクターの種類別の評価

第7章 遺伝子治療市場：アプローチ別の評価

第8章 遺伝子治療市場：投与経路別の評価

第9章 遺伝子治療市場：地域別の評価

第10章 競合情勢

第11章 企業プロファイル

List of Tables

List of Figures

Gene Therapy Market Report Highlights

By Type Therapeutic Area Outlook (Revenue, USD Million, 2020-2034)

By Vector Type Outlook (Revenue, USD Million, 2020-2034)

By Approach Outlook (Revenue, USD Million, 2020-2034)

By Route of Administration Outlook (Revenue, USD Million, 2020-2034)

By Regional Outlook (Revenue, USD Million, 2020-2034)

Table of Contents

Chapter 1. Introduction

Chapter 2. Executive Summary

Chapter 3. Research Methodology

Chapter 4. Gene Therapy Market Insights

Chapter 5. Gene Therapy Market Assessment by Therapeutic Area

Chapter 6. Gene Therapy Market Assessment by Vector Type

Chapter 7. Gene Therapy Market Assessment by Approach

Chapter 8. Gene Therapy Market Assessment by Route of Administration

Chapter 9. Gene Therapy Market Assessment by Region

Chapter 10. Competitive Landscape

Chapter 11. Company Profiles

第1章イントロダクション

第2章エグゼクティブサマリー

第3章分析手法

第4章遺伝子治療市場の洞察

第5章遺伝子治療市場：治療領域別の評価

第6章遺伝子治療市場：ベクターの種類別の評価

第7章遺伝子治療市場：アプローチ別の評価

第8章遺伝子治療市場：投与経路別の評価

第9章遺伝子治療市場：地域別の評価

第10章競合情勢

第11章企業プロファイル